Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines. In addition, it exports its products. The company was founded in 2004 and is based in Chengdu, China.

Sector

Healthcare

Industry

Biotechnology

CEO

Wu, Hongbo

Employees

620

Website

www.kangh.com

IPO Date

2020-06-16

Headquarters

No. 182, Beijing Road, Eco & Tech Dev Zn, Chengdu, Sichuan Province, 610100, China

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

Chengdu Kanghua Biological Products 300841

Chengdu Kanghua Biological Products Earnings Call Summary

Chengdu Kanghua Biological Products Earnings

Transcripts

Events

About Chengdu Kanghua Biological Products Co., Ltd.

Chengdu Kanghua Biological Products
300841